7/13/2006
Genetic variation predicts response to heart medication
Researchers at the University of Maryland School of Medicine in Baltimore and the University of Colorado School of Medicine in Denver have identified a common genetic variation that could help determine whether a person with heart failure would benefit from beta-blockers, a class of drugs used to treat chronic heart failure.
"For the first time, we have a genetic test that will help guide us to the best treatment for individual patients with heart failure and provide what has been called personal medicine," says the study's principal investigator, Stephen B. Liggett, M.D., professor of medicine and physiology at the University of Maryland School of Medicine and director of its cardiopulmonary genomics program. "This personalized therapy, based on genes, gives us an opportunity to tailor therapy in a way that we really were never able to do before," says Dr. Liggett.
Genetic variation found that predicts response to heart failure medication
"For the first time, we have a genetic test that will help guide us to the best treatment for individual patients with heart failure and provide what has been called personal medicine," says the study's principal investigator, Stephen B. Liggett, M.D., professor of medicine and physiology at the University of Maryland School of Medicine and director of its cardiopulmonary genomics program. "This personalized therapy, based on genes, gives us an opportunity to tailor therapy in a way that we really were never able to do before," says Dr. Liggett.
Genetic variation found that predicts response to heart failure medication
